Verneuil's disease is a chronic, suppurative dermatosis involving the apocrine glands with a severe impact on the quality of life. There is no standard treatment for this disease, and the drugs usually prescribed are often poorly effective.
Therefore, a new therapeutic approach based on zinc salts was investigated with 22 patients, mainly from grade I or II in Hurley’s clinical staging. All patients included had previously been prescribed a treatment (antibiotic, isotretinoin, surgery or anti-androgens), which was inefficient. The patients were treated with 90 mg of zinc gluconate per day (15 mg zinc, 6 times per day).
A clinical response in all patients was observed, with 8 complete remissions and 14 partial remissions. When complete remission was obtained, the treatment was progressively decreased; however, relapses occurred when reaching 2-4 capsules per day, depending on the severity of the disease.
Recurrence disappeared when the dosage was increased again, suggesting that the treatment is suppressive rather than curative. The treatment was well tolerated (4/22 patients experiencing side-effects, mainly gastro-intestinal), and this is crucial in the context of a chronic disease strongly affecting quality of life.
Carla Holmes | Source: alphagalileo
Further information: www.karger.com
More articles from
Studies and Analyses:
Older people may need less sleep, study finds
25.07.2008 | University of Surrey
Toxic Chemicals Found in Common Scented Laundry Products, Air Fresheners
25.07.2008 | University of Washington
Object intermediate between normal supernovae and gamma-ray bursts found
25.07.2008 | Physics and Astronomy
Leeds project aims to boost parents’ confidence in MMR choices as measles rates rise
25.07.2008 | Health and Medicine
COROT’s new find orbits Sun-like star
25.07.2008 | Physics and Astronomy